Bispecifics Unlocked
The Lock-In™ Platform quickly gets you to bispecific candidates that can go through to Cell Line Development.
No redesign. No rework. No mispairing.
Overview
Lock-In™ is a new ATUM proprietary platform that brings IgG-like stability, performance and developability to bispecific molecules.
Move quickly from monoclonal sequences to bispecific lead candidates, with a path into development.
Improve timelines from lead optimization through cell line development
Complicated bispecifics may perform great in early testing, but run into roadblocks in preclinical testing or manufacturing. The Lock-In platform looks like a monoclonal antibody – more importantly, it performs like a monoclonal antibody in testing and development.
Benefits:
- “IgG-like” for straightforward development, testing and manufacturing.
- No light chain mispairing.
- Retains binding activity and potency.
- Ease of transfer into Cell Line Development.
Discovery to Lead Optimization – without Reengineering
Developing a common light chain is often the first roadblock in bispecific development. With traditional methods, months of precious development time is spent to force the structure into a manufacturable drug – if ever.
By leveraging lightningHEK transient screening, you can quickly evaluate multiple mAb sequences to identify the best candidates within weeks.
Build and test the sequence combinations the way you want. Binding activity with Lock-In matches the original monoclonal sequence. The graph shows Lock-In Fabs compared to the wild-type Fab. No reengineering, no sequence changes needed.
Functionally Active
In cell-based killing assays, Lock-In performs the same as the original bispecific antibody (in this case, mosunetuzumab). Since Lock-In functions just as well as other scaffolds, it’s never too late to switch!
